We discuss studies documenting the undertreatment of diabetic macular edema and possible strategies for alleviating it with Dr. Matthew Starr, Assistant Professor, Mayo Clinic, Rochester, Minnesota.

In this episode, we discuss promising results of gene therapy, administered suprachoroidally, for the treatment of nonproliferation diabetic retinopathy without macular edema with Charles Wykoff, MD, Ph.D., Retina Consultants of Houston.

We discuss promising Phase 2 results from Nanoscope regarding the use of optogenetics for treatment of retinal degenerations with Allen Ho, MD, Professor of Ophthalmology, Wills Eye Hospital.

We discuss the early results of the use of artificial intelligence in the management of macular disorders with Dr. Pearse Keane, the world's first Professor of Artificial Medical Intelligence, University College London, Moorfields Eye Hospital.

We discuss with Dr. Rajesh C. Rao, Leonard Miller Professor of Ophthalmology, Kellogg Eye Center, University of Michigan, the results of a Phase I trial exploring the use of stem cells injected subretinally in eyes with geographic atrophy. The results are promising.

We discuss the early results of gene therapy of neovascular AMD by intravitreal administration of the vector with Dr. Glenn Yiu, Professor of Ophthalmology, University of California, Davis.

We discuss the long term results of the Truckee Study, a stage 4 clinical trial in the treatment of neovascular AMD with faricimab with Dr. Arshad Khanani from Sierra Eye Associates, Reno, Nevada.

We discuss the use of a tyrosinase kinase inhibitor, EY-1901, for the treatment of diabetic macular edema with Dr. Yasha Modi, New York University, and Manhattan Eye Ear and Throat Hospital, New York.

We discuss early results from the study of photobiomodulation for the treatment of dry AMD with Dr. David Boyer, Adjunct Professor of Clinical Ophthalmology, Keck School of Medicine of USC, Roski Eye Institute.

We review long term results from the PHOTON Study with Eric Schneider, MD, Tennessee Retina, Nashville, TM.

We review the latest results from the Regenexbio sub retinal gene therapy program with Robert Avery MD, California Retina Consultants, Santa Barbara, CA

We discuss whether pegcetacoplan therapy of geography atrophy affects the progression of dry AMD with Paul Hahn MD PhD of PH Retina, Nanuet, New York.

We discuss the observation that resolution of retinal fluid at one month in eyes with nAMD treated with aflibercept 8mg may herald longer duration treatment intervals at week 96 with Michael Stewart,, MD, Knights Templar Professor of Ophthalmology, Mayo Clinic, Jacksonville, Florida.

We discuss the current state of the Good Days charitable foundation with Dr. Michael Lai, MD. PhD, Retina Group of Washington, Assistant Clinical Professor, Georgetown University School of Medicine

We discuss the long term results of the Oaks, Derby, and GALE studies looking at the benefit of early treatment of geographic atrophy in AMD with Dr. Roger Goldberg of Walnut Creek, California.

We discuss management of eyes with both geographic atrophy and neovascular AMD with Dr. Ted Leng of the Byers Eye Institute, Stanford University School of Medicine

We review the 6 month results of the Davio 2 trial of the Durayvu TKI delivery system for maintenance therapy of neovascular AMD with Dr. Carl Regillo of Wills Eye Hospital.

We discuss the latest promising results from the GALE extension study of pegcetacoplan with Dr. Ashkan Abbey of Texas Retina Associates

We discuss the promising phase I results of the Helios trial studying AXPAXLI TKI inhibitor implant for diabetic retinopathy with Dr. Dilsher Dhoot of California Retina Consultants.

We discuss the use of non steroidal inflammatory agents in the management of central serous chorioretinopathy with Dr. Michael Singer of San Antonio, Texas